Device Trial Radar · NCT07510919
CGM in Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Apr 21, 2026
Primary completion
May 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- IsalaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medisch Spectrum Twente
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management. This study is designed as a multicenter, non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management in two stroke centers in the Netherlands. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \>10 mmol/L) during the first 72 hours of hospitalization. Researchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients. Participants will: * Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management * Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization * Receive glucose management according to the assigned monitoring strategy, based on a standardized insulin correction scheme applied uniformly across all participating centers
Conditions
- Acute Ischemic Stroke
- Diabetes (DM)
- Diabetes Type 2
- Hyperglycemia
- Stroke
Interventions
Continuous Glucose MonitoringDevice
Continuous glucose monitoring using the FreeStyle Libre systems (Abbott Diabetes Care) to measure interstitial glucose levels through a subcutaneous sensor that continuously records glucose concentrations during hospitalization.
Point-of-Care TestingDiagnostic test
Intermittent glucose monitoring using point-of-care finger-prick capillary blood glucose measurements according to the hospital glucose management protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time spent in hyperglycemia (>10 mmol/L)Time frame: During the first 72 hours of hospitalization
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Medisch Spectrum Twente
Enschede, Netherlands · Not yet recruiting
Isala Zwolle
Zwolle, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.